A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT02588625
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Conditions
Scleroderma
Interventions
DRUG:
BMS-986020
OTHER:
Placebo
Sponsor
Bristol-Myers Squibb